Medications for the treatment of pulmonary arterial hypertension

PHA Canada
Aug 10, 2022
1 min read

Updated: Oct 7, 2024

PHA Canada's very own Dr. Sanjay Metha, Dr. Lisa Mielniczuk, and others have published a study in the European Respiratory Review. Read about their systemic review of PAH medications here.

Recent Posts

Time to diagnosis matters for patients with PAH

This study identified factors associated with a delayed diagnosis of PAH and found that earlier diagnosis (<6 months) and treatment initiation were associated with significantly improved survival. Mor

Review finds selexipag is well tolerated in children

A review of 12 studies evaluating selexipag in pediatric patients with pulmonary arterial hypertension found that it improved functional capacity and mPAP, especially when added to existing therapies.

Sotatercept might help treat portopulmonary hypertension

Patients with portopulmonary hypertension were not included in clinical trials for sotatercept. This case report found that sotatercept helped one patient with portopulmonary hypertension, who was the

Comments